April 20, 2018 09:13 AM EDTUpdated April 18, 12:14 PM
R&D
Pharma

No­var­tis CEO Vas Narasimhan is rais­ing the bar on sec­ond-gen can­cer drug stud­ies

John Carroll

Editor & Founder

No­var­tis $NVS has been no­tice­ably ab­sent from the cen­ter ring of PD-1/L1 re­search, qui­et­ly ad­vanc­ing its own check­point as an in-house as­set to match up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times